IL-2联合自体LAK细胞治疗晚期恶性黑色素瘤、肾癌、肝癌疗效评价

IL2 Combined with LAK Cells in the Treatment of Malignant Melanoma and Cancers of Kidney, Liver, Lung

本研究观察了ＩＬ－２联合ＬＡＫ细胞对经病理学证实的４３例恶黑，肾癌，肝癌，肺癌和大肠癌在综合治疗中的作用及其毒副作用。采用ＣＳ－３０００ｐｌｕｓ人体血细胞分离机采集患者自体淋巴细胞，２０万单位ＩＬ－２，肌肉或静脉输注每天１次，每周４次，连续２周；ＬＡＫ细胞（ＩＬ－２浓度为１０００Ｕ／ｍｌ，细胞浓度（２～５）×１０６，３７℃，５％ＣＯ２培养１～２周）每次回输１０亿细胞，第４和第８天回输为一疗程。疗效评价标准采用Ⅲ期临床试验规定标准，结果显示其疗效与病种有关即为恶黑３３％，肾癌１１％，肝癌１０％，肺癌６％；平均总有效率为９％，同时还观察到同一病种内疗效与剂量呈正相关。在治疗中未观察到毒副作用。在ＬＡＫ细胞培养中又观察到经反复治疗的患者其淋巴细胞对ＩＬ－２的反应性增强扩增时间缩短，呈现出免疫反应加快现象，能否说明ＩＬ－２治疗可提高患者免疫力尚需进一步证实。

The role of IL2/LAK in the treatment of 43 cases of malignant melanoma, renal, hepatic and pulmonary cancers was assessed. A dose of 200 000 unit IL2 was given 4 times /week for 2 weeks (iv/im). After cultured for 1 to 2 weeks the LAK cells were infused back to the patients on the 4th and 8th day. The effects varied with variety of the malignant tumor. The effective rates were 33%, 11%, 10% and 6% in malignant melanoma, renal , hepatic and pulmonary cancers respectively. The overall response rate was 9%, no sideeffects were observed.The results suggest that the effectiveness related with the variety of the tumors and the dose of IL2 used. Enhanced reactivity and shortened expansion time of lymphocytes to IL2 were observed but its enhancement of immunity of the patients remains to be determined. 